EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas

Yoshitaka Inoue iD, Jun-Ichirou Yasunaga iD

Cells · 2025

DOI: 10.3390/cells14171306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Yoshitaka Inoue und 1 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell lymphomas (TCLs) are generally associated with a poorer prognosis compared to B-cell lymphomas, and allogeneic hematopoietic cell transplantation (allo-HCT) is often considered for eligible patients. One of the primary reasons for the inferior outcomes in TCLs has been the lack of effective novel agents for many years, resulting in a continued reliance on traditional cytotoxic chemotherapy regimens. However, over the past decade, several novel agents with promising efficacy against TCLs have been developed. Notably, many of these agents not only exert direct anti-tumor effects but also modulate host immune function, raising clinical questions regarding the optimal integration of these agents with allo-HCT. In this review, we aim to summarize how the use of novel agents that are approved for the treatment of TCLs—such as mogamulizumab, brentuximab vedotin, lenalidomide, histone deacetylase inhibitors, enhancer of zeste homolog inhibitors, and immune checkpoint inhibitors—before or after allo-HCT may impact transplantation outcomes in patients with TCLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphoma, T-CellAnimalsBrentuximab VedotinHistone Deacetylase InhibitorsImmune Checkpoint InhibitorsLenalidomideTransplantation, HomologousHumansAntineoplastic AgentsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

T-cell lymphomasallogeneic hematopoietic cell transplantationbrentuximab vedotinenhancer of zeste homolog 1/2 (EZH1/2) inhibitorshistone deacetylase inhibitors (HDACis)lenalidomidemogamulizumabnovel agents

Substanzen

Brentuximab VedotinHistone Deacetylase InhibitorsImmune Checkpoint InhibitorsLenalidomidemogamulizumabAntineoplastic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA.
  • Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA.
  • Department of Hematology, Kumamoto University, Kumamoto 860-8556, Japan.

ORCID-Profile: Yoshitaka Inoue, Jun-Ichirou Yasunaga

Förderung

  • JSPS KAKENHI

Zitieren

APA

Inoue, Y., & Yasunaga, J. I. (2025). Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas. Cells. https://doi.org/10.3390/cells14171306

Vancouver

Inoue Y, Yasunaga JI. Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas. Cells. 2025. doi:10.3390/cells14171306

BibTeX
@article{Inoue2025,
  author = {Inoue, Yoshitaka and Yasunaga, Jun-Ichirou},
  title = {Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14171306}
}
Kostenlos starten →